PubMed Health⌕ Search

Biomedical subjects

F Edsmyr

Publications and source records attributed to F Edsmyr.

At least 37 records · Page 2Linked to original sources

Distribution of lymphocyte subsets following radiation therapy directed to different body regions.

Local radiation therapy may severely deplete the recirculating pool of lymphocytes as manifested by a reduction of blood lymphocyte counts. There is considerable controversy, however, concerning the changes of the distributions of subsets of blood lymphocytes during the acute and late phases after irradiation. This report provides evidence that radiation therapy directed to different anatomic sites may change the distribution of subsets of blood lymphocytes in different ways. For instance, during the acute phase after radiation therapy for breast cancer there is a more extensive reduction of the proportion of lymphocytes with receptors for C3 than that of lymphocytes with receptors for sheep erythrocytes (characteristics of B- and T-cells respectively). Such a difference, however, was not observed in groups of patients receiving pelvic irradiation. The controversy in the literature concerning the distribution of lymphocyte subsets after irradiation may thus in part be due to the fact that the patients examined have received radiation therapy to different body regions.

Adult↗

[Adriamycin instillations in carcinoma in situ of the bladder].

Several authors have described the regressive effect of the instillation of adriamycin on the cell appearance of carcinoma in situ. This applies to both weekly and monthly administration. The problem lies in the interpretation of the cytologic picture after instillation. DNA analysis could possibly improve the diagnostic reliability.

Carcinoma in Situ↗

Prediction of survival and recurrence in bladder carcinoma.

We have followed a large population of patients receiving radiation treatment for bladder carcinoma with respect to survival and recurrence-free survival. Bivariate and multivariate life table analyses have been performed using a set of independent variables. The most important were T class, grade (G), urinary carcinoembryonic antigen (U-CEA) taken before treatment and cytological analysis 4 months after treatment. We compared the usual way of classifying a patient (T + G) with the combination of U-CEA and cytology since the latter two variables seemed to have great prognostic importance. The analyses show that T + G gives the best significance for survival (p = 0.0003) while U-CEA and cytology is better for recurrence-free survival (rho = 0.0002). 0.0002).

Actuarial Analysis↗

Chemotherapy in non-seminomatous testicular tumours stage I.

Chemotherapy improves the survival rate of patients with disseminated teratoid testicular tumours, but patients without evidence of metastatic spread are not usually given further treatment after retroperitoneal lymphadenectomy because of the high toxicity of most drugs; 10 to 20% of these patients die later with widespread disease. In an earlier series of 24 patients from our hospital the survival rate in stage I disease was below 70%. Since 1973, when we began to use adjuvant chemotherapy in this group, there have been no relapse.

Adolescent↗

Peyronie's disease: experience of local treatment with Orgotein.

22 patients with Peyronie's disease have been treated with Orgotein, the new anti-inflammatory metalloprotein which pronounced superoxide dismutase activity patients with long-standing and severe symptoms were selected for the trial. The drug was given monthly by injection into the indurated areas of penis. In 19 patients, where the sexual act could be performed with difficulties or the penile angulation made intercourse impossible, marked improvement was seen or normal function was restored. No adverse reactions by Orgotein were seen.

Adult↗

Effect of pepleomycin on peripheral lymphocytes.

The blood lymphocyte population was monitored in 6 patients with advanced malignant tumors who were treated with large doses of a new cytotoxic drug termed pepleomycin. It was observed that the size of the cell population, its cellular composition, mitogen stimulations and natural killer activity did not change in any consistent ways during or after treatment. It is concluded that pepleomycin does not directly affect the lymphocytic population.

Adenocarcinoma↗

Orgotein efficacy in ameliorating side effects due to radiation therapy.

Orgotein efficacy in minimizing the local side effects induced by radiotherapy, administered to patients suffering from bladder or prostate cancer, was studied in 3 double-blind clinical trials. Assessment parameters such as efficacy, signs and symptoms of bladder disease were chosen as follows: incontinence, pain, dysuria, cystoscopic picture, maximal voiding volume, voiding frequency (day and night), diarrhoea, amount of anti-diarrhoea preparations consumed. In the first study orgotein was administered in a dose of 4 mg, 15-30 minutes after radiotherapy. Orgotein was found to be statistically significant superior to placebo when assessed according to the above mentioned criteria. Side effects that would have compelled stopping the orgotein therapy did not develop. In the second trial 50 patients suffering from prostatic carcinoma received after each radiotherapy (5,400 rad during 6 weeks) 8 mg orgotein or placebo. The radiotherapy-induced side effects were less common in the orgotein group than in the placebo group. The third clinical trial was conducted according to the same protocol as the two previous ones. Fifty patients with either prostate or bladder cancer were given orgotein or placebo in conjunction with radio-therapy. Only data of 26 out of 50 are yet available. These data show in agreement with two previous mentioned trials a significant superiority of orgotein compared to placebo.

Anti-Inflammatory Agents↗

Assessment of serial CEA determinations in urine of patients with bladder carcinoma.

Carcinoembryonic antigen (CEA) levels in urine and serum from 294 patients with bladder cancer in varying stages have been clinically evaluated. All urine samples were obtained from patients with intact renal function and without bacterial infection in the bladder. The samples were collected before, during, and at follow-up examination after radiotherapy. They were perchloric acid extracted before being assayed in a double-antibody radioimmunoassay. The geometric mean of urine CEA levels for patients with primary tumors of Stage T1 or T2 was significantly lower than that for those with Stage T3 or T4 disease. The urine CEA levels for patients with tumors of various histologic grades did not differ. The urine CEA levels decreased from before to after radiation treatment of the primary tumor. Patients with recurrence within six months after undergoing primary treatment had higher initial mean urine CEA levels than did those without evidence of recurrence. The prognostic information for recurrence was limited to the more advanced tumors. Differences were also found between the means of samples taken before recurrence and after treatment of recurrent tumors; with regression of the tumor, a lower mean urine CEA level was found; with progression, a higher value. Urine CEA levels before any treatment were higher when the patients had a short survival time. Serum CEA levels were not related to stage or grade of the primary bladder tumor but levels were slightly elevated with metastases. The determination of urine CEA levels seems to be useful in the follow-up of patients with bladder carcinoma because when initially high, it adds to the information of the T classification and predicts early recurrence, and the monitoring of individual patients after primary treatment is useful for detecting recurrence.

Aged↗

Bestatin treatment and the peripheral lymphocyte population in cancer patients.

Bestatin, a substance produced by Streptomyces olivoreticuli, inhibits certain cell-membrane-associated enzymes and has been shown to augment immune responses in experimental animals. We have determined whether bestatin medication changed the peripheral lymphocyte population in 15 advanced cancer patients. After 2 weeks of daily, 30 mg oral bestatin medication, the lymphocyte counts remained essentially unchanged, but the frequency of E-rosette-forming lymphocytes increased. In vitro stimulation of the lymphocytes with PHA or PPD remained essentially unchanged while the natural-killer activity of the lymphocyte population increased in most patients. Bestatin treatment caused no detectable side effects.

Adjuvants, Immunologic↗

Intravesical therapy with adriamycin in patients with superficial bladder tumors.

An 80-mg dose of adriamycin was given intravesically once a month to 58 patients with superficial transitional cell tumor of the bladder. Complete cytological remission was achieved in all 11 patients with previously untreated, flat carcinoma in situ lesions. In 19 carcinoma in situ patients, who were previously treated by other means, cytological remission occurred in 74%. In T1 and T2 papillary tumor remission occurred in 65 and 20%, respectively. Minor local side effects were observed.

Administration, Topical↗

Natural killer activity in peripheral lymphocyte population following local radiation therapy.

The natural killer (NK) activity of peripheral lymphocytes against 51Cr-labelled Chang or K562 cells was tested using a 4 h release assay before and after postoperative radiation therapy for mammary carcinoma. NK activity against K562 was significantly reduced at completion of therapy (a total target dose of 45.0 Gy) and restituted 3 to 4 months later. NK activity against Change cells exhibited a slight but non-significant decline at completion of therapy followed by an overshoot 3 to 4 months later. The frequency of Fc-IgG receptor bearing lymphocytes was decreased at completion of therapy and largely restored after 3 to 4 months.

Adult↗

Irradiation combined with bleomycin treatment of synchronized cells in culture under oxic and hypoxic conditions.

Bleomycin-treated cells are sensitized to radiation delivered under oxic conditions both in the early S and G2 phases of the cycle, irradiated under hypoxic conditions, sensitization occurs only in the early S phase. This difference in the sensitizing effect of the drug is discussed in regard to the possible clinical advantages of a combined treatment ot tumors with irradiation and Bleomycin.

Animals↗

Estramustine versus conventional estrogenic hormones in the initial treatment of highly or moderately differentiated prostatic carcinoma. A randomized study.

In a prospective randomized multicenter trial patients with highly or moderately differentiated prostatic carcinoma, previously untreated, were allotted either to oral Estramustine phosphate or to intramuscular polyestradiol phosphate plus oral ethinyl estradiol. As regards frequency and duration of tumour remission there was no statistical difference between the two groups. Nor did they differ significantly with respect to adverse reactions. This is an interim report and will be followed later on by a final evaluation.

Bone Neoplasms↗

Estramustine phosphate therapy in poorly differentiated carcinoma of the prostate.

Ninety patients with poorly differentiated prostatic carcinoma have been treated with Estramustine phosphate (Estracyt). Seventeen of them had clinically metastases and had had no previous therapy. Seventy-three were initially given oestrogens and/or irradiation. Objective response was observed in 59%. The best effect was seen in patients primarily untreated.

Acid Phosphatase↗

Cyclophosphamide-prednisolone therapy in advanced prostatic carcinoma.

Cyclophosphamide and prednisolone therapy was given to 83 patients with hormone-resistant disseminated carcinoma of the prostate. In 7 cases there were objective signs of regression of metastases. Significant reduction of elevated acid phosphatase activity was recorded in 11 cases, in 2 of them to normal range. 55 patients experienced pain relief, 26 of them very good. In the majority of cases duration of the remission was shorter than 6 months, in 2 cases it lasted more than a year.

Acid Phosphatase↗